OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Puri on the Rationale to Evaluate Real-World Multiomic Characterization of SCLC Subtypes

August 2nd 2021

Sonam Puri, MD, discusses the rationale to evaluate the real-world multiomic characterization of small cell lung cancer subtypes.

Dr. Mamdani on Evaluating the Immunogenicity of STK11/TP53 Co-Mutations in NSCLC

August 2nd 2021

Hirva Mamdani, MD, discusses the rationale to evaluate the immunogenicity of STK11 and TP53 co-mutations in non–small cell lung cancer.

Dr. Naqash on the Results of a Tumor Profiling Study in STK11/TP53 Co-Mutated NSCLC

August 2nd 2021

Abdul Rafeh Naqash, MD, discusses the results of a tumor profiling study in STK11 and TP53 co-mutated non–small cell lung cancer.

Dr. Cohen on the Clinical Implications of the GALAXY Trial in CRC

August 2nd 2021

Stacey A. Cohen, MD, discusses the clinical implications of the ongoing GALAXY trial, part of the CIRCULATE-Japan project, in colorectal cancer.

Dr. Roboz on the Importance of Genomic Analysis in AML

August 2nd 2021

Gail J. Roboz, MD, discusses the importance of utilizing genomic analysis to help guide treatment decisions in patients with acute myeloid leukemia.

Dr. Manasanch on Outcomes With Elranatamab in Multiple Myeloma

August 2nd 2021

Elisabet E. Manasanch, MD, discusses outcomes seen with elranatamab in patients with relapsed or refractory multiple myeloma.

Dr. Reckamp on the Significance of ALTA in ALK+ NSCLC

August 1st 2021

Karen L. Reckamp, MD, discusses the significance of the final results of the ALTA trial in patients with ALK-positive non–small cell lung cancer.

Dr. Willmott on Using Genetic Testing to Inform PARP Inhibitor Selection in Ovarian Cancer

July 29th 2021

Lyndsay Willmott, MD, discusses selecting among available PARP inhibitors for the treatment of patients with ovarian cancer based on genetic testing results.

Dr. Abida on the Clinical Significance of the TRITON2 Study in mCRPC

July 29th 2021

Wassim Abida, MD, PhD, discusses the clinical significance of the results from the phase 2 TRITON2 trial in metastatic castration-resistant prostate cancer.

Dr. Masrouha on the Challenges of Surgical Removal of Chordoma Tumors

July 29th 2021

Karim Masrouha, MD, discusses the challenges of surgically removing chordoma tumors.

Dr. Tolaney on Key Findings From the ExteNET Trial in HER2+ Breast Cancer

July 29th 2021

Sara M. Tolaney, MD, MPH, discusses data from the phase 3 ExteNET trial utilizing neratinib in the treatment of patients with HER2-positive breast cancer.

Dr. Liao on Outcomes With Ivosidenib in Advanced Cholangiocarcinoma

July 28th 2021

Chih-Yi Liao, MD, discusses outcomes reported with ivosidenib in patients with advanced cholangiocarcinoma.

Dr. Basho on the Evolution of Therapeutic Sequencing in HER2+ Breast Cancer

July 28th 2021

Reva K. Basho, MD, discusses the evolution of therapeutic sequencing in HER2-positive breast cancer.

Dr. Morris Discusses Ongoing Research With 177Lu-PSMA-617 in Prostate Cancer

July 28th 2021

Michael J. Morris, MD, discusses ongoing research efforts with 177Lu-PSMA-617 in prostate cancer.

Dr. Monk on the Utility of PARP Inhibitors as Maintenance Therapy in Ovarian Cancer

July 28th 2021

Bradley J. Monk, MD, FACS, FACOG, discusses the utility of PARP inhibitors as maintenance therapy in ovarian cancer.

Dr. Dreicer on the Clinical Implications of the JAVELIN Bladder 100 Trial in Urothelial Cancer

July 28th 2021

Robert Dreicer, MD, discusses the clinical implications of the phase 3 JAVELIN Bladder 100 trial in locally advanced or metastatic urothelial cancer.

Dr. Roboz on Recent Therapeutic Developments in AML

July 27th 2021

Gail J. Roboz, MD, discusses recent therapeutics developments in the treatment of patients with acute myeloid leukemia.

Dr. Rosenberg on the Potential Clinical Implications of the GRIFFIN Trial in Multiple Myeloma

July 27th 2021

Aaron Seth Rosenberg, MD, MS, discusses the potential clinical implications of the phase 2 GRIFFIN trial in multiple myeloma.

Dr. Van Tine on the Rationale to Evaluate Catequentinib in Synovial Sarcoma

July 27th 2021

Brian A. Van Tine, MD, PhD, discusses the rationale to evaluate catequentinib in synovial sarcoma.

Dr. Roeker on the Emerging Role of MRD in CLL

July 27th 2021

Lindsey Roeker, MD, discusses the emerging role of minimal residual disease as a predictive end point in chronic lymphocytic leukemia.